Mast cells and the neurofibroma microenvironment

Blood

Volumn 116, Issue 2, 2010, Pages 157-164

  Staser, Karl ^a   Yang, Feng Chun ^a   Clapp, D Wade ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUORODEOXYGLUCOSE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROFIBROMIN; PLATELET DERIVED GROWTH FACTOR; RAF PROTEIN; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANGIOGENESIS; ASTROCYTE; CANCER GROWTH; CARCINOGENESIS; CELL LINEAGE; CELL PROLIFERATION; CHIMERA; FIBROBLAST; GENE DELETION; HAPLOTYPE; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM; HETEROZYGOSITY LOSS; HETEROZYGOTE; HISTOLOGY; HUMAN; IMMUNOPRECIPITATION; KNOCKOUT GENE; MAST CELL; MELANOCYTE; MYELODYSPLASTIC SYNDROME; NEUROFIBROMA; PAPILLOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; FEMALE; GENETICS; IMMUNOLOGY; NEUROFIBROMATOSIS; PRESCHOOL CHILD;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; MAST CELLS; NEUROFIBROMA; NEUROFIBROMATOSIS 1; PIPERAZINES; PYRIMIDINES;

EID: 77955481914     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-242875     Document Type: Review

References (80)

1. Akenside M. Observations on cancers. Med Trans Coll Phys Lond. 1768;1:64-92.
2. Tilesius von Tilenau W. Historia pathologica singularis Cutis Turpitudinis: Jo Godofredi Rheinhardi viri L annorum. Leipzig, Germany: SL Crusius; 1793.
3. Morse RP. Neurofibromatosis type 1. Arch Neurol. 1999;56(3):364-365.
4. von Recklinghausen F. Uber die Multiplen Fibrome der Haut und ihre Beziehung zu Multiplen Neuromen. Berlin: August Hirschwald; 1882.
5. Greggio H. Les cellules granuleuses (Mastzellen) dans les tissus normaux et dans certaines maladies chirurgicales. Arch Med Exp. 1911;23:323-375.
6. Friedman J, Gutmann DH, Maccollin M, Riccardi, VM. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 3rd ed. Baltimore, MD: The Johns Hopkins University Press; 1999.
7. Riccardi VM. Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser. 1981;17(2):129-145.
8. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981;305(27):1617-1327.
9. Riccardi VM. Neurofibromatosis: past, present, and future. N Engl J Med. 1991;324(18):1283-1285.
10. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62(3):599-608. (Pubitemid 20263229)
11. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993;10(3):335-343.
12. Gutmann DH, Boguski M, Marchuk D, Wigler M, Collins FS, Ballester R. Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis. Oncogene. 1993;8(3):761-769.
13. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63(4):843-849.
14. DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992;69(2):265-273.
15. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249(4965):181-186.
16. Viskochil D, Cawthon R, O'Connell P, et al. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol. 1991;11(2):906-912. (Pubitemid 21895439)
17. Bader JL. Neurofibromatosis and cancer. Ann N Y Acad Sci. 1986;486:57-65.
18. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell. 2009;4(5):453-463.
19. Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med. 1993;117(10):996-999.
20. Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007;26(32):4609-4616. (Pubitemid 47067408)
21. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296(5569):920- 922.
22. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593-604.
23. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell. 2008;135(3):437-448.
24. Li F, Munchhof AM, White HA, et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Hum Mol Genet. 2006;15(11):1921-1930.
25. Munchhof AM, Li F, White HA, et al. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum Mol Genet. 2006;15(11):1858-1869.
26. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12(2):137-143.
27. Zhu Y, Harada T, Liu L, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development. 2005;132(24):5577-5588.
28. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003;63(24):8573-8577. (Pubitemid 38064027)
29. Yeh TH, Lee da Y, Gianino SM, Gutmann DH. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia. 2009;57(11):1239-1249.
30. Lasater EA, Bessler WK, Mead LE, et al. Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum Mol Genet. 2008;17(15):2336-2344.
31. Cui Y, Costa RM, Murphy GG, et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell. 2008;135(3):549-560.
32. Yan J, Chen S, Zhang Y, et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet. 2008;17(7):936-948.
33. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7(3):353-361.
34. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994;8(9):1019-1029.
35. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172-2176. (Pubitemid 129516295)
36. Ingram DA, Yang FC, Travers JB, et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med. 2000;191(1):181-188.
37. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63(1):225-233.
38. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63(1):213-224.
39. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988;335(6185):88-89.
40. Nocka K, Tan JC, Chiu E, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J. 1990;9(6):1805-1813. (Pubitemid 20170012)
41. Tan JC, Nocka K, Ray P, Traktman P, Besmer P. The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase. Science. 1990;247(4939):209-212. (Pubitemid 120031311)
42. Atit RP, Mitchell K, Nguyen L, Warshawsky D, Ratner N. The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol. 2000;114(6):1093-1100.
43. Bajenaru ML, Donahoe J, Corral T, et al. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia. 2001;33(4):314-323.
44. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol. 2002;22(14):5100-5113. (Pubitemid 34700701)
45. Zhu Y, Romero MI, Ghosh P, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001;15(7):859-876.
46. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am J Pathol. 1993;142(4):965-974.
47. Ryan JJ, Klein KA, Neuberger TJ, et al. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res. 1994;37(3):415-432.
48. Starkey JR, Crowle PK, Taubenberger S. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer. 1988;42(1):48-52.
49. Gounaris E, Erdman SE, Restaino C, et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A. 2007;104(50):19977-19982.
50. Elpek GO, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001;54(12):940-944. (Pubitemid 34032889)
51. Dabbous MK, Haney L, Nicolson GL, Eckley D, Woolley DE. Mast cell modulation of tumour cell proliferation in rat mammary adenocarcinoma 13762NF. Br J Cancer. 1991;63(6):873-878.
52. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med. 2001;193(6):F23-26.
53. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
54. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
55. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
56. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001;20(1):97-105.
57. Yang FC, Ingram DA, Chen S, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest. 2003;112(12):1851-1861.
58. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990;348(6297):125-132. (Pubitemid 120029052)
59. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991;349(6305):117-127.
60. Hall A. The cellular functions of small GTP-binding proteins. Science. 1990;249(4969):635-640. (Pubitemid 20259079)
61. Hall A. Signal transduction through small GTPases-a tale of two GAPs. Cell. 1992;69(3):389-391.
62. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851-859.
63. Fountain JW, Wallace MR, Brereton AM, et al. Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17. Am J Hum Genet. 1989;44(1):58-67.
64. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144-148.
65. Zhang YY, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 1998;187(11):1893-1902.
66. Ingram DA, Zhang L, McCarthy J, et al. Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood. 2002;100(10):3656-3662. (Pubitemid 35303936)
67. Khalaf WF, Yang FC, Chen S, et al. K-ras is critical for modulating multiple c-kit-mediated cellular functions in wild-type and Nf1+/- mast cells. J Immunol. 2007;178(4):2527-2534.
68. McDaniel AS, Allen JD, Park SJ, et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-infunction phenotypes in Nf1+/- mast cells. Blood. 2008;112(12):4646-4654.
69. Hiatt K, Ingram DA, Huddleston H, Spandau DF, Kapur R, Clapp DW. Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells. Am J Pathol. 2004;164(4):1471-1479.
70. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem. 2001;276(10):7240-7245. (Pubitemid 33648144)
71. Yang FC, Kapur R, King AJ, et al. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity. 2000;12(5):557-568.
72. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med. 2001;194(1):57-69.
73. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-3310.
74. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26(22):3227-3239. (Pubitemid 46763017)
75. Yang FC, Chen S, Clegg T, et al. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet. 2006;15(16):2421-2437.
76. Jaakkola S, Peltonen J, Riccardi V, Chu ML, Uitto J. Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures. J Clin Invest. 1989;84(1):253-261. (Pubitemid 19170117)
77. Wu J, Williams JP, Rizvi TA, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008;13(2):105-116.
78. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808-4817.
79. Arbiser JL, Flynn E, Barnhill RL. Analysis of vascularity of human neurofibromas. J Am Acad Dermatol. 1998;38(6 Pt 1):950-954.
80. Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol. 1997;17(2):862-872. (Pubitemid 27044386)